Kun Ma, Linna Ma, Tianjiao Huang, Yue Wang, Guanlan Zhong, Cong Gao, Zhiyu Zhou, Jie Luo
{"title":"阿立哌唑、溴隐亭和卡麦角林治疗高催乳素血症的有效性和安全性：系统综述和网络荟萃分析。","authors":"Kun Ma, Linna Ma, Tianjiao Huang, Yue Wang, Guanlan Zhong, Cong Gao, Zhiyu Zhou, Jie Luo","doi":"10.1080/14740338.2024.2416918","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the efficacy and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia (HPRL) using network meta-analysis.</p><p><strong>Method: </strong>We searched PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and China Biology Medicine disc (CBMdisc) for randomized controlled trials (RCTs). The quality of the included studies was assessed using the Cochrane risk-of-bias tool, and data were analyzed using RevMan 5.4, R 4.3.3, and Stata 17.</p><p><strong>Results: </strong>44 RCTs involving a total of 3886 patients were finally included. The results showed that at 12 week of treatment, cabergoline plus conventional therapy had optimal efficacy in reducing prolactin (PRL) levels. Cabergoline plus conventional therapy was most effective in reducing PRL levels in patients with non-drug-induced HPRL. Aripiprazole plus conventional therapy had optimal efficacy in reducing PRL levels in patients with antipsychotics-induced or antidepressant-induced HPRL. Bromocriptine was the most efficacious intervention in improving estrogen (E<sub>2</sub>) levels.</p><p><strong>Conclusion: </strong>Three dopamine receptor agonists (DAs) have different advantages in improving serum PRL and E<sub>2</sub> levels in HPRL patients.</p><p><strong>Prospero id: </strong>CRD42024510695.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis.\",\"authors\":\"Kun Ma, Linna Ma, Tianjiao Huang, Yue Wang, Guanlan Zhong, Cong Gao, Zhiyu Zhou, Jie Luo\",\"doi\":\"10.1080/14740338.2024.2416918\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To assess the efficacy and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia (HPRL) using network meta-analysis.</p><p><strong>Method: </strong>We searched PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and China Biology Medicine disc (CBMdisc) for randomized controlled trials (RCTs). The quality of the included studies was assessed using the Cochrane risk-of-bias tool, and data were analyzed using RevMan 5.4, R 4.3.3, and Stata 17.</p><p><strong>Results: </strong>44 RCTs involving a total of 3886 patients were finally included. The results showed that at 12 week of treatment, cabergoline plus conventional therapy had optimal efficacy in reducing prolactin (PRL) levels. Cabergoline plus conventional therapy was most effective in reducing PRL levels in patients with non-drug-induced HPRL. Aripiprazole plus conventional therapy had optimal efficacy in reducing PRL levels in patients with antipsychotics-induced or antidepressant-induced HPRL. Bromocriptine was the most efficacious intervention in improving estrogen (E<sub>2</sub>) levels.</p><p><strong>Conclusion: </strong>Three dopamine receptor agonists (DAs) have different advantages in improving serum PRL and E<sub>2</sub> levels in HPRL patients.</p><p><strong>Prospero id: </strong>CRD42024510695.</p>\",\"PeriodicalId\":12232,\"journal\":{\"name\":\"Expert Opinion on Drug Safety\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14740338.2024.2416918\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2416918","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
目的采用网络荟萃分析评估阿立哌唑、溴隐亭和卡麦角林治疗高泌乳素血症（HPRL）的疗效和安全性：我们检索了 PubMed、Cochrane Library、Embase、Web of Science、中国国家知识基础设施（CNKI）、万方数据库、VIP 和中国生物医学文献数据库（CBMdisc）中的随机对照试验（RCT）。使用 Cochrane 偏倚风险工具对纳入研究的质量进行评估，并使用 RevMan 5.4、R 4.3.3 和 Stata 17 对数据进行分析：最终纳入了 44 项研究，共涉及 3886 名患者。结果显示，在治疗 12 周时，卡贝戈林联合常规疗法在降低催乳素（PRL）水平方面具有最佳疗效。卡麦角林加常规疗法对降低非药物诱发的 HPRL 患者的 PRL 水平最为有效。阿立哌唑联合常规疗法对降低抗精神病药物诱发或抗抑郁药物诱发的HPRL患者的PRL水平具有最佳疗效。在改善雌激素（E2）水平方面，溴隐亭是最有效的干预措施：结论：三种多巴胺受体激动剂（DAs）在改善 HPRL 患者血清 PRL 和 E2 水平方面具有不同的优势：crd42024510695.
The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis.
Objective: To assess the efficacy and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia (HPRL) using network meta-analysis.
Method: We searched PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and China Biology Medicine disc (CBMdisc) for randomized controlled trials (RCTs). The quality of the included studies was assessed using the Cochrane risk-of-bias tool, and data were analyzed using RevMan 5.4, R 4.3.3, and Stata 17.
Results: 44 RCTs involving a total of 3886 patients were finally included. The results showed that at 12 week of treatment, cabergoline plus conventional therapy had optimal efficacy in reducing prolactin (PRL) levels. Cabergoline plus conventional therapy was most effective in reducing PRL levels in patients with non-drug-induced HPRL. Aripiprazole plus conventional therapy had optimal efficacy in reducing PRL levels in patients with antipsychotics-induced or antidepressant-induced HPRL. Bromocriptine was the most efficacious intervention in improving estrogen (E2) levels.
Conclusion: Three dopamine receptor agonists (DAs) have different advantages in improving serum PRL and E2 levels in HPRL patients.
期刊介绍：
Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports.
Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
